Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA)...

Full description

Bibliographic Details
Main Authors: Babak Nami, Hamid Maadi, Zhixiang Wang
Format: Article
Language:English
Published: MDPI AG 2018-09-01
Series:Cancers
Subjects:
Online Access:http://www.mdpi.com/2072-6694/10/10/342